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A B S T R A C T
Overall drug overuse, including psychotropic, is the Croatian reality. Therefore, in between 2000 and 2012, the inter-
ventions to control drug overspending were undertaken. The main aims of the study are: to determine the morbidity
trends of mental disorders registered in family medicine (FM), the trends in psychotropic drug utilization and to identify
whether the trends of utilization have any relation to the interventions. The results indicate that mental disorders repre-
sent a high disease burden in Croatia. It was also present a higher burden of psychotropic drug utilization; second
ranked in the total drug utilization during the nine-year follow up period. The utilization of psycholeptic’s, was even
higher; from 2004 to 2008; those drugs were ranked first in terms of utilization. Between 20–25% of Croatia’s total
health care budget is usually spent on drugs. The interventions that are currently being implemented to control drug uti-
lization have not brought about any changes.
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Introduction
Several years ago, the British Medical Journal started
a campaign of »Too Much Medicine« based on the litera-
ture documenting cases of over-investigation, over-diag-
nosis and over-treatment1–6. A similar situation is occur-
ring in Croatia; overall drug overuse, including psycho-
tropic drugs, is well documented in the literature7,8.
Therefore, between 2000 and 2012, three groups of inter-
ventions or regulations to control drug overspending
were undertaken, mainly by the Croatian Health Insur-
ance Fund (CHIF). The first group of interventions tar-
geted family doctors (FDs) that were under contract with
CHIF, as the main prescribers of medications. In 2003, a
restriction on the number of prescriptions that FDs
could prescribe annually per patients was introduced by
CHIF. In the beginning, the number of the prescription
refill forms was restricted to five for each patient, then
that restriction was increased to eight for each patient on
the list. A restriction was also placed on the physical
availability of the prescription refill forms in order to ob-
tain the allotted yearly number in four portions, every
three months9. In 2007, this then changed to a financial
restriction, based on the age-related amount of money
that should be spent each year for each patient on the
list10. A restriction, accompanying by financial penalties,
still exists as a part of the FD’s contract with CHIF11.
The second group of interventions was related to the
insurers, the publicly insured patients, through the in-
troduction of a co-payment. It has always been a rule
that publicly insured patients must individually contrib-
ute to their medical costs. The amount of money they
had to pay was usually symbolic for the majority of them
and furthermore, many patients were released, primarily
based on their socio-economic status12. Gradually, the
sum became greater and additional voluntary insurance
was introduced in 2000 to cover medical costs, including
the costs of a prescription13. However, many patients did
not accept that option, and a much higher level of partici-
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pation, known as administrative taxes, was introduced in
200514. The third group of interventions was related to
the lists of basic drugs that were available for the insured
patients and additional lists of drugs that should be par-
tially paid. Negotiations that were made with the phar-
maceutical firms to lower the drug costs also belong in
this group of interventions15.
Until now, no research studies have investigated lon-
ger trends in the consumption of psychotropic drugs, es-
pecially in relation to the interventions and regulations
for controlling consumption. Therefore, this study was
undertaken with the following aims: 1) to determine the
morbidity trends of mental disorders registered in family
medicine (FM) in Croatia; 2) to determine the trends in
psychotropic drug utilization; and 3) to identify whether
the trends in psychotropic drug utilization have any rela-
tion to the regulations introduced in between 2000 and
2012.
Methods
The study is observational and retrospective, based
on routinely collected data. From the Croatian Health
Service Yearbooks, the Croatian Institute of Public Health,
from 2004 to 2012, the morbidity data recorded in family
medicine (FM) were extracted16. Data from the Year-
books were based on FM electronic records and the mor-
bidity data were registered based on the Instructions for
data registrations and collection17. Due to those Instruc-
tions, the first visit of a patient suffering from a chronic
condition in a calendar year is registered as a morbidity
case. If a patient suffers from an acute disease, only the
first visit is registered as a morbidity case. All subse-
quent, follow-up visits are not registered as morbidity.
This could continue until a disease was cured, and if the
patient felt well the case would be closed. If the same pa-
tient returns in the consecutive year for the same acute
diagnosis, it is registered as a new morbidity case. In
Croatia, the International Disease Classification, version
X, (ICD-X) is used to register morbidity. Mental health
problems are registered under F diagnoses.
However, not all F diagnoses are registered within the
Croatian Health Service Yearbooks. Mental health prob-
lems are grouped into seven broad categories: dementia
(F00-F03), alcohol problems (F10), illicit drug problems
(F11-F19), schizophrenia and psychosis (F20-F29), neu-
rosis, stress and affective disorders (F40-F48), mental re-
tardation (F70-F79) and other mental and behavioral
disorders, in which depressive and personality disorders
are included. Morbidity is registered according to the pa-
tient’s age group: 0–6 years, 7–19 years, 20–64 years and
over 65 years. All data were collected exactly in the way
they were presented in the yearbooks and for the consec-
utive years.
The following data were obtained from the Yearly Re-
ports of the Croatian Agency for Medicinal Products and
Medical Devices (HALMED): total drug utilization and
the utilization of psychotropic drugs, types and amounts
of drugs presented in DDD per 1000 inhabitants, per
days (DDD/TID) for the years ranging from 2004 to 2012.
The types of drugs are registered using the ATC classifi-
cation index in which psychotropic drugs are listed under
label N as psycholeptics N05 and psychoanaleptics N06.
All the data on total drug utilization and of the utiliza-
tion of psycholeptics N05 and psychoanaleptics N06 were
collected. However, data on particular drugs from those
two groups were missing if some of the drugs did not be-
long to the 30 most commonly used drugs for the years
ranging from 2004 to 2012. The missing data were the
reason why the data on drugs labelled as N06 were col-
lected from the year 2006 and why data on hospital utili-
zation and out-of-hospital utilization were collected from
the years ranging from 2007 to 201218.
All of the collected data were related to the psycho-
tropic drugs that are usually covered by the Croatian In-
stitute of Health Insurance, as these are part of the reim-
bursement for the prescriptions issued for out-of-hos-
pital care or are part of the hospital reimbursement. In
addition, there is a possibility that a doctor could issue a
permanent receipt and the patient would have to directly
pay the pharmacy for the medication. The data on that
type of utilization was also collected. To determine finan-
cial utilization, DDD/TID was used as the measure for
drug utilization and to indicate the amount of money
(kunas) required to pay for the drugs18.
The collected data were analyzed using Microsoft Of-
fice (Excel and Access) software. The results are pre-
sented in the form of frequency and, graphically, the
trends are displayed as line charts.
Results
The results are presenting in two categories: morbid-
ity trends and psychotropic drug utilization.
Morbidity trends for mental illnesses registered
in Croatian FM
In terms of morbidity, between 2004 and 2012, mental
disorders were usually ranked fifth or sixth. In 2012,
20.3% of adult patients visiting FDs were diagnosed as
having mental disorders.
The number of mental disorders registered in FP
nearly doubled from 1995 to 2012. This is especially the
case from 2008 to 2011 and then the number of mental
disorders decreased from 2011 to 2012. The most promi-
nent increase (3.3 times) occurred in the group of disor-
ders labelled as other mental and behavioral disorders,
including depressive and personality disorders. The pre-
valence of neurosis, stress and affective disorders (F40-
F48) increased 1.6 times. Only alcohol problems (F10)
showed a decreased trend, while the number of cases of
illicit drug problems (F11-F19) increased as well (Figure 1).
A large number of the mental disorders registered in
FP were diagnosed in people in the following two age
groups: 20–64 year and over 65 years, with similar in-
creased trends during the entire follow-up period; 1.9
times in age group 20–64 and 2.0 times in the group over
M. Rapi} et al.: Trends in Psychotropic Drug Utilization in Croatia, Coll. Antropol. 38 (2014) Suppl. 2: 37–42
38
65 years. Less than 5% of all cases belong to the 0–6 year
and 7–19 year age groups (Figure 2).
A morbidity structure for the two groups of mental
disorders with the highest increase in morbidity in rela-
tion to age is presented at the Figure 3 and Figure 4.
A slightly higher increased trend of neurosis, stress
and affective disorders is registered in the over 65 age
group (2.0 times) than in the 20–64 age group (1.6 times).
Only1.4% of the morbidity cases are registered in chil-
dren and young people (0–19 years) (Figure 3).
The increased trends of mental and behavioral disor-
ders labelled as others in the over 65 age group were
higher (4.4 times) than the trends in the 20–64 age group
(3.2 times). These increased trends were also registered
in children, aged 0–6 years (1.7 times), and in young peo-
ple, aged 7–19 years (2.2 times) (Figure 4).
Utilization of psychotropic drugs
As seen in Figure 5 and Figure 6, the total utilization
of psychotropic drugs and the utilization of the mostly
frequently used psychotropic drugs, psycholeptics (N05)
and psychoanaleptics (N06), are presented as DDD/TID.
The financial utilization of psychotropic drugs (based on
kunas) is presented at Figure 7.
Total utilization of psychotropic drugs shows that the
trends continuously increased from 103.6 DDD/TID in
2005 to 148.4 DDD/TID in 2010. During the rest of the
follow-up years, that trend was stable. Much of the utili-
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Fig. 1. Trends in total morbidity and the structure of mental dis-
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Fig. 2. The morbidity structure for mental disorders (F diagno-
sis, ICD-10) registered according to the patient’s age in family
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Fig. 3. Trends in the morbidity structure for neurosis, stress and
affective disorders (F40-F48) registered according to the pa-
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Fig. 4. Trends in the morbidity structure in other mental and be-
havioural disorders, including depressive and personality disor-


















Fig. 5. Trends in the total utilization of psychotropic drugs, in-
cluding psycholeptics (N05) and psychoanaleptics (N06), in
DDD/TID in Croatia, 2004–2012.
zation belongs to the psycholeptics (N05). After a slight
decrease until 2006, the utilization continuously increa-
sed until 2012: ranging from 66.9 DDD/TID in 2005 to
90.3 DDD/TID in 2012. The trend in the utilization of the
psychoanaleptics (N06) increased even more, from 11.3
DDD/TID in 2005 to 26.4 DDD/TID in 2012 (Figure 5).
In the nine-year follow-up period, psychotropic drugs
ranked second in total overall drug utilization, just after
cardiovascular drugs. In 2012, full daily doses of psycho-
tropic drugs were used by 50,282,135 people, or 14.8% of
the Croatian adult population. As a separate group, psy-
choleptics (N05) were ranked first in utilization from
2004 to 2008; after that, they were ranked second. At the
same time, the utilization ranking of psychoanaleptics
(N06) increased from 16 to 11.
Within the group of psycholeptic drugs, anxiolytics,
particularly benzodiazepines, were the mostly widely
used drugs, and their utilization trends continuously in-
creased, especially after 2008. Of that class of drugs, di-
azepam was most frequently used and its utilization in-
creased from 18.7 DDD/TID in 2004, to 31.6 DDD/TID in
2012. The utilization trends for oxazepam decreased,
while the utilization trends for alprazolane increased,
from10.8 DDD/TID in 2004 to 23.7 DDD/TID in 2012.
The utilization trends for psychoanaleptic (N06) drugs
increased as well, including use of the antidepressants,
sertraline and paroxetin; however, until 2007, those
drugs were not among the 30 most utilized medications
(Figure 6).
The total financial utilization (spending) for psy-
chotropic drugs steadily increased 1.4 times, from
608,881,055 kunas in 2004, to 810,530,218 kunas in
2012. The increase in the financial utilization trends was
slightly higher for the psycholeptics (N05) than it was for
the psychoanaleptics (N06) (Figure 7).
In 2004, the overall financial outlay for drugs in
Croatia was 3.82 billion HRK (around 501 million EUR).
Approximately 90% of that total cost was spent on drugs
in the prescription regime and, therefore, the drugs were
reimbursable by CHIF. The total costs were relatively
uniform from 2004 to 2007, while in the last few years
the costs increased by 32.7%, from 3.82 billion HRK in
2004 to 5.07 billion HRK in 2012. In 2004, 15.9% of the
total spending went to psychotropic drugs and in 2012
the total spending for psychotropic drugs increased to
21.5%.
Beginning in 2007, all hospital and out-of-hospital
utilization of psychotropic drugs were recorded in yearly
reports. However, in general, the data on out-of-hospital
utilization is more important. For example, in 2007,
those drugs were utilized 54.2 DDD/1000/day in out-of-
-hospital settings and 1.3 DDD/TID in hospital settings.
In 2012, utilization of those drugs in out-of-hospital set-
tings was 53.5 DDD/TID, and in hospital settings it was
2.43 DDD/TID. In comparison, the most used out-of-hos-
pital drugs were benzodiazepines, among them diaze-
pam, while hospitals used different psychotropic drugs,
including anti-psychotics.
The out-of-hospital utilization of psychotropic drugs
that patients had to pay for on their own was a part of
the total utilization data. Again, the most frequently
used type of those drugs were benzodiazepines, among
them diazepam. However, the utilization trend slightly
decreased beginning in 2005. In 2005, the utilization
data for those drugs was: 8.5 DDD/TID for benzodiaz-
epine and 3.5 DDD/TID for diazepam. In 2012, the utili-
zation for those drugs was: 5.8 DDD/TID for benzodiaz-
epine and 2.0 DDD/TID for diazepam.
Discussion
The results indicate that mental disorders represent a
high disease burden in Croatia. Approximately 20% of
the adult population was labelled as having a mental dis-
order and most of the diagnoses were for mental and be-
havioral disorders labelled as others, in which depressive
and personality disorders were included. The neurosis
and affective disorders were also with high proportion;
this is especially true for patients in the over 65 age
group. The results also indicate a higher burden of psy-
chotropic drug utilization; which ranked second in the
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Fig. 6. Trends in utilization of specific drugs from the group of
























Fig. 7. Trends in the total financial utilization for psychotropic
drugs and psycholeptics (N05) and psychoanaleptics (N06) in
kunas, in Croatia, 2004–2012.
total drug utilization during the nine-year follow up pe-
riod. While the number of mental disorders decreased
from 2011 to 2012, the same decreased is not observed in
drugs consumption in 2012 compared to 2011.
The utilization of psycholeptics, as a separate group,
was even higher; from 2004 to 2008; those drugs were
ranked first in terms of utilization; after that, those
drugs were ranked second in total utilization. Among the
psycholeptic drugs, benzodiazepines, particularly diaze-
pam, were most often used. It seems that the previously
mentioned interventions that were introduced to control
drug utilization did not result in lower utilization for
psychotropic drugs. In contrast, a continuous increase in
utilization was present when the first intervention was
introduced in 2003, and the utilization increased even
faster, especially after 2008, when many other interven-
tions were introduced, including restrictive measures
that were applied to the contracted FDs.
According to WHO, the incidence of mental disorders
is increasing all over the world19. In Croatia, mental dis-
orders are common, occupied the fourth place in 1995
and fifth in 2012, with 5.8% of the total morbidity re-
corded in FP20. The results of a study on people in the
city of Zagreb, conducted by Poli}-Vi`intin and associ-
ates, showed similar results. Neurosis and affective dis-
orders were ranked as the eighth most common mental
health condition21. It is difficult to judge the role of the
Diagnostic and Statistical Manual of Mental Disorders.
Even DSM-4 classification has raised many questions,
and the DSM-5 classification has raised even more. Dow-
rick and Frances reanalyzed the results of American
studies on depression among Medicare beneficiaries ap-
plying DSM-5. They found that although the prevalence
of major depression remained the same, the prevalence
of mild and moderate depression increased rapidly. One
of their major conclusions was: »Turning grief and other
life stresses into mental disorders represents medical in-
trusion on personal emotions«22.
With a high level of certainty, it could be said that the
phenomenon of over-utilization of psychotropic drugs
does exists in Croatia. The second ranking for total utili-
zation of drugs, the first ranking for utilization of psy-
choleptic drugs and the high use of benzodiazepines, par-
ticularly diazepam, are obvious arguments in favor of
such a consideration. The results from other studies in
Croatia are similar to the results from this study. In the
study conducted by [timac and associates, nervous sys-
tem agents were among the sixth most-often used drugs
in Croatia in 2009, with great variations between the
counties23. In the study comparing the utilization of psy-
cho-pharmaceuticals in Croatia and in Scandinavian
countries, the consumption of psycholeptic drugs was
three times higher in Croatia than it was Finland and
Denmark, and it was 3.6 times higher in Croatia than in
Norway. Of the psycholeptics, diazepam was the drug
that was most often used24.
The cost of those drugs also places a high burden on
financial expenditures. Between 20–25% of Croatia’s to-
tal health care budget is usually spent on drugs. Around
16% of the total drug costs are spent on psychotropic
drugs. The costs for psycho-pharmaceuticals are increas-
ing all over the world25,26, and the burden is even more
serious because of the global financial crisis, especially in
Croatia27,28.
The strengths of this study come from its nine-year
follow-up, which is a time line long enough to determine
the permanent nature of the over-utilization of psycho-
tropic drugs. This study’s strength also arises from the
fact that the data were collected from the official sources
usually used for planning different levels of health ser-
vices. This study also makes it possible to compare the
findings of different studies, because other studies are
very often based on the same sources. However, the na-
ture of the data only allows for the determination of the
trends. Deeper insights, especially in terms of causal re-
lations, are not possible in this type of research. Further-
more, some data were missing, which limited the study’s
results; but, that also indicates that reporting should be
improved and made completely accessible to the public.
Even with those limitations, the results of this study
should be seriously taken into the considerations by dif-
ferent stakeholders within the health care system. A
higher level of decision makers should be aware that the
types of interventions that were implemented between
2000 and 2010 did not result in any changes. Therefore,
evidence-based effective interventions should be taken
into consideration for the future29. The role of patients at
both the individual and public levels should not be ne-
glected and prevention interventions should also be ad-
dressed30.
Conclusions
Four main conclusions related to the Croatian situa-
tion can be drawn from the study results. The first is that
the prevalence of mental disorders is rapidly increasing.
The second conclusion is that the over-utilization of
psychotropic drugs is already present in Croatia. The
third conclusion is that the interventions that are cur-
rently being implemented to control drug utilization
have not brought about any changes. The fourth conclu-
sion is that new research studies are needed in Croatia to
gain a deeper understanding of these two phenomena:
over-diagnosis of metal disorders and over-utilization of
psychotics.
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DEVETOGODI[NJE KRETANJE POBOLA OD DU[EVNIH BOLESTI I KORI[TENJA
PSIHOTROPNIH LIJEKOVA U HRVATSKOJ: PREVI[E DIJAGNOZA I PREVI[E KONZUMACIJE?
S A @ E T A K
Istra`ivanje je provedeno s ciljem da se utvrdi trend pobola od mentalnih bolesti registriranih u ordinacijama lije~ni-
ka obiteljske medicine u Hrvatskoj, da se utvrdi potro{nja psihofarmaka od 2004. do 2012. godine, te da se procjeni da li
je potro{nja psihofarmaka povezana s regulatornim mjerama done{enim u tom razdoblju. U istra`ivanju je kori{tena
statisti~ko-deskriptivna retrospektivna metoda, temeljena na podacima o pobolu registriranom u ambulantama obitelj-
ske medicine publiciranim u Hrvatskim zdravstveno-statisti~kim ljetopisima, od 2004.–2012. godine. Podaci o potro{nji
psihofarmaka dobiveni su iz godi{njih izvje{}a Hrvatske agencije za lijekove i medicinske proizvode (HALMED). Dobi-
veni rezultati pokazali su da se pobol od mentalnih bolesti zna~ajno pove}ao u promatranom razdoblju, te sukladno
tome i potro{nja psihofarmaka. Najve}a potro{nja u promatranom razdoblju zabilje`ena je u grupi psihileptika, a me|u
njima diazepama. Na psihotropne lijekove izdvojena su i zna~ajna nov~na sredstva. Izgleda da mjere uvedene s ciljem
kontrole potro{nje lijekova nisu imale nikakav utjecaj na potro{nju psihofarmaka.
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